Non-bank asset sales to push securitisation volumes to ₹2 trillion in FY20, says ICRA. Rupee steady ahead of US economic data. RBI imposes ₹7-cr fine on SBI for violation of various regulatory guidelines. Markets are likely to be firm, HDFC AMC and Federal Bank shares in focus. Asian shares tick up, US data, earnings in focus ahead of Fed.

Call :   91-9990248471
Mail id :   support@shristocktips.com

Tue - 16 Jul 2019

:
:
Calender | Holiday

Past Performance of Investment Package in November 2016 with 80%-85% Accuracy


Date Script in Cash Trade Type Enter Target StopLoss Result Quantity Profit/loss
02-Nov-2016 AUROPHARMA Sell Intraday Ard 793-795 784-780 799 Booked at 570.55 400 Rs. 2180
03-Nov-2016 AXISBANK Buy (5-15 days) Ard 474-477 495-525 460 Booked at 486 400 Rs. 4800
Total Profit : Six Thousand Nine Hundred and Eighty Rs. 6,980

Date Script in Future Trade Type Enter Target StopLoss Result Quantity Profit/loss 4 lots
03-Nov-2016 AXISBANK Buy (5-15 days) Ard 474-477 495-525 460 Booked at 486 1200 Rs. 48000
04-Nov-2016 SUNPHARMA 700 CE Buy (0-4 days) Ard 11-09 20-32 4 Booked at 13.50 600 Rs. 7200
10-Nov-2016 BANKNIFTY 20300 CE Nov Buy (0-3 days) Ard 90-80 130-180-250 58 Made High 234 40 Rs. 16000
10-Nov-2016 AXISBANK Fut 510 CE Buy (0-4 days) Ard 8.50-6 18-25 2 Booked at 12 1200 Rs. 19200
11-Nov-2016 CIPLA 540 PE Buy (0-3 days) Around 6.50-5 11-60. 2.5 Booked at 10 1000 Rs. 14000
16-Nov-2016 CENTURYTEX 760 CE Buy (0-3 days) Around 36-33 45-55 28 Target Hit 1100 Rs. 66000
Total Profit : One Lakh Seventy Thousands Four Hundred Rs. 1,70,400
go top

SEBI REG.NO INH100001955      Powered by Shristockstips.com

Hurry Up Join Fut/Option/Nifty/Investment For 3 Month Only Rs.13,000/- + 1 Pkg Free. To Join Click Here- Our site is objectively based on pure Technical Analysis . All other content like Indian Business News, market commentary etc are all to give additional ambiance & make the reader more enlightening. For more information please read our Disclaimer , Term & Conditions And FaQ . Note - Accuracy of calls subject to disclaimer